28 April 2024 - For the first time in 15 years women with an invasive form of early breast cancer that has a high risk of returning after initial treatment will now have access to an additional medicine thanks to the Albanese Government expanding the listing of abemaciclib (Verzenio) on the Pharmaceutical Benefits Scheme.

From 1 May 2024, Verzenio will be expanded on the PBS to treat patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, lymph node positive, invasive, resected early breast cancer at high risk of disease recurrence.

Read Minister for Health press release

MAESTrO Insight - the PBAC recommended the PBS listing of abemaciclib for use in combination with standard adjuvant endocrine therapy for the treatment of patients with early, invasive, lymph node positive, resected, hormone receptor positive, HER2 negative breast cancer at high risk of disease recurrence.